Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials

Journal of Diabetes and its Complications

Volumn 31, Issue 7, 2017, Pages 1237-1242

  Mazidi, Mohsen ^a   Karimi, Ehsan ^b   Rezaie, Peyman ^b   Ferns, Gordon A ^c  

^a INSTITUTE OF GENETICS AND DEVELOPMENTAL BIOLOGY   (China)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF BRIGHTON   (United Kingdom)

Author keywords

C reactive protein; Glucagon like peptide 1 receptor agonist; Meta analysis; Randomized controlled trials; Type 2 diabetics

Indexed keywords

C REACTIVE PROTEIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; EXENDIN 4; GLP1R PROTEIN, HUMAN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; LIRAGLUTIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PEPTIDE; VENOM;

DATA SYNTHESIS; DERSIMONIAN LAIRD METHOD; GENERIC INVERSE VARIANCE METHOD; HUMAN; META ANALYSIS; METHODOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; ANTAGONISTS AND INHIBITORS; BLOOD; DOWN REGULATION; DRUG EFFECTS; HYPERGLYCEMIA; HYPOGLYCEMIA; IMMUNOLOGY; METABOLISM;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOMARKERS; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; DOWN-REGULATION; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLYCATED HEMOGLOBIN A; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VENOMS;

EID: 85009104318     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2016.05.022     Document Type: Review

References (39)

1. Masters, S.L., Latz, E., O'Neill, L.A., The inflammasome in atherosclerosis and type 2 diabetes. Science translational medicine., 3, 2011, 81ps17.
2. Mazidi, M., Heidari-Bakavoli, A., Zadeh, S.K., Azarpazhooh, M.R., Nematy, M., Safarian, M., et al. Dietary cholesterol, but not dietary fatty acid intake, varies with serum hs-CRP concentrations in individuals free of any history of cardiovascular disease. Eur J Clin Nutr 70 (2016), 1454–1457, 10.1038/ejcn.2016.92 [Epub 2016 Sep 28].
3. Mazidi, M., Gao, H.-K., Vatanparast, H., Kengne, A.P., Impact of the dietary fatty acid intake on C-reactive protein levels in US adults. Medicine (Baltimore), 96, 2017, e5736, 10.1097/MD.0000000000005736.
4. Nan, W., Shan, T., Qian, X., Ping, W., Bing, G., Ying, L., PPARα agonist prevented the apoptosis induced by glucose and fatty acid in neonatal cardiomyocytes. J Endocrinol Invest 34 (2011), 271–275.
5. Mazidi, M., de Caravatto, P.P., Speakman, J.R., Cohen, R.V., Mechanisms of Action of Surgical Interventions on Weight-Related Diseases: the Potential Role of Bile Acids. Obes Surg 27 (2017), 826–836, 10.1007/s11695-017-2549-1.
6. Doyle, M.E., Egan, J.M., Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 113 (2007), 546–593.
7. Holst, J.J., The physiology of glucagon-like peptide 1. Physiol Rev 87 (2007), 1409–1439.
8. Shyangdan, D.S., Royle, P.L., Clar, C., Sharma, P., Waugh, N.R., Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis. BMC Endocr Disord, 10, 2010, 1.
9. Drucker, D.J., Nauck, M.A., The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 (2006), 1696–1705.
10. Tzefos, M., Harris, K., Brackett, A., Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults. Ann Pharmacother 46 (2012), 68–78.
11. Zinman, B., Schmidt, W., Moses, A., Lund, N., Gough, S., Achieving a clinically relevant composite outcome of an HbA1c of < 7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme. Diabetes Obes Metab 14 (2012), 77–82.
12. Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151 (2009), 264–269 [W64].
13. Phan, K., Tian, D.H., Cao, C., Black, D., Yan, T.D., Systematic review and meta-analysis: techniques and a guide for the academic surgeon. Ann Cardiothorac Surg 4 (2015), 112–122.
14. Jadad, A.R., Moore, R.A., Carroll, D., Jenkinson, C., Reynolds, D.J.M., Gavaghan, D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 17 (1996), 1–12.
15. Higgins, J.P.T., Green, S., Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.2. 2009, The Cochrane Collaboration, London.
16. Sutton, A.J., Abrams, K.R., Jones, D.R., Sheldon, T.A., Song, F., Methods for meta-analysis in medical research. 2000, John Wiley & Sons, West Sussex, UK.
17. Mazidi, M., Rezaie, P., Ferns, G.A., Vatanparast, H., Impact of probiotic administration on serum C-reactive protein concentrations: Systematic review and meta-analysis of randomized control trials. Nutrients, 9, 2017 [pii: E20] 10.3390/nu9010020.
18. Hozo, S.P., Djulbegovic, B., Hozo, I., Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol, 5, 2005, 13.
19. Mazidi, M., Rezaie, P., Ferns, G.A., Gao, H.K., Impact of different types of tree nut, peanut, and soy nut consumption on serum C-reactive protein (CRP): A systematic review and meta-analysis of randomized controlled clinical trials. Medicine (Baltimore), 95, 2016, e5165 [PMID: 27858850] 10.1097/MD.0000000000005165.
20. Higgins, J., Green, S., Cochrane handbook for systematic reviews, version 5.0. 2. 2009, The Cochrane Collaboration [OpenURL].
21. Mazidi, M., Rezaie, P., Karimi, E., Kengne, A.P., The effects of bile acid sequestrants on lipid profile and blood glucose concentrations: A systematic review and meta-analysis of randomized controlled trials. Int J Cardiol 227 (2017), 850–857, 10.1016/j.ijcard.2016.10.011 [Epub 2016 Oct 11].
22. Mazidi, M., Rezaie, P., Vatanparast, H., Kengne, A.P., Effect of statins on serum vitamin D concentrations: a systematic review and meta-analysis. Eur J Clin Invest 47 (2017), 93–101, 10.1111/eci.12698 [Epub 2016 Dec 13].
23. Duval, S., Tweedie, R., Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56 (2000), 455–463.
24. Borenstein, M., Hedges, L., Higgins, J., Rothstein, H., Comprehensive Metaanalysis (Vers. 2). 2005, Englewood Cliffs, NJ, Biostat. Inc.
25. Kelly, A.S., Bergenstal, R.M., Gonzalez-Campoy, J.M., Katz, H., Bank AJ, Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial. Cardiovasc Diabetol 11 (2012), 1327–1335.
26. Fan, H., Pan, Q., Xu, Y., Yang, X., Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease. Arq Bras Endocrinol Metabol 57 (2013), 702–708.
27. Wu, J.-d., Xu, X.-h., Zhu, J., Ding, B., Du, T.-x., Gao, G., et al. Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitus. Diabetes Technol Ther 13 (2011), 143–148.
28. Derosa, G., Maffioli, P., Ferrari, I., D'Angelo, A., Fogari, E., Palumbo, I., et al. Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients. Endocrine Journal 57 (2010), 777–786.
29. Bunck, M.C., Diamant, M., Eliasson, B., Cornér, A., Shaginian, R.M., Heine, R.J., et al. Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care 33 (2010), 1734–1737.
30. Faurschou, A., Gyldenløve, M., Rohde, U., Thyssen, J.P., Zachariae, C., Skov, L., et al. Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients–a randomized placebo-controlled trial. J Eur Acad Dermatol Venereol 29 (2015), 555–559.
31. Liang, Z., Wu, Q., Chen, B., Yu, P., Zhao, H., Ouyang, X., Effect of laparoscopic Roux-en-Y gastric bypass surgery on type 2 diabetes mellitus with hypertension: a randomized controlled trial. Diabetes Res Clin Pract 101 (2013), 50–56.
32. Gallwitz, B., Glucagon-like peptide-1 analogues for type 2 diabetes mellitus. Drugs 71 (2011), 1675–1688.
33. Kuhadiya, N.D., Dhindsa, S., Ghanim, H., Mehta, A., Makdissi, A., Batra, M., et al. Addition of Liraglutide to Insulin in Patients With Type 1 Diabetes: A Randomized Placebo-Controlled Clinical Trial of 12 Weeks. Diabetes Care 39 (2016), 1027–1035.
34. Tan, K.C., Wat, N.M., Tam, S.C., Janus, E.D., Lam, T., Lam, K.S., C-reactive protein predicts the deterioration of glycemia in Chinese subjects with impaired glucose tolerance. Diabetes Care 26 (2003), 2323–2328.
35. Demir, T., Cömlekci, A., Demir, O., Gülcü, A., Calıskan, S., Argun, L., et al. A possible new risk factor in diabetic patients with erectile dysfunction: homocysteinemia. J Diabetes Complicat 22 (2008), 395–399.
36. Giannessi, D., Maltinti, M., Del Ry, S., Adiponectin circulating levels: a new emerging biomarker of cardiovascular risk. Pharmacol Res 56 (2007), 459–467.
37. Marso, S.P., Poulter, N.R., Nissen, S.E., Nauck, M.A., Zinman, B., Daniels, G.H., et al. Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J 166 (2013), 823–830.e5.
38. Nuesch, E., Trelle, S., Reichenbach, S., Rutjes, A.W., Tschannen, B., Altman, D.G., et al. Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. BMJ, 341, 2010, c3515.
39. Sterne, J.A., Gavaghan, D., Egger, M., Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 53 (2000), 1119–1129.